*Only the 1D chart reflects 15-min delayed quotes during market hours. Other timeframes update after market close.
Walgreens Boots Alliance's upcoming earnings report on June 26, 2025, is set against a backdrop of strategic shifts and financial challenges, with the company's market cap standing at approximately $9.87 billion. Notably, the whisper number of $0.40 per share suggests a cautious optimism among investors, slightly above the EPS estimate of $0.33. This comes after a turbulent fiscal year marked by a significant net loss in Q1 2025, driven by store closures and opioid litigation costs. Despite these hurdles, Walgreens has shown resilience in its international operations, with steady growth in the Germany wholesale business and Boots UK sales. However, the U.S. Retail Pharmacy segment continues to face headwinds, impacting overall profitability. Analysts are closely watching the company's ability to navigate these challenges while maintaining revenue growth, projected at $36.84 billion for the quarter. As Walgreens transitions towards a potential acquisition by Sycamore Partners, the market remains attentive to how these developments will influence future earnings and strategic direction.
Walgreens Boots Alliance, Inc. is an American pharmaceuticals holding company headquartered in Deerfield, Illinois. It owns the pharmacy chains Walgreens and Boots, as well as several pharmaceutical manufacturing, wholesale, and distribution companies.
Average Sentiment Score:
Overall Sentiment: